Suppr超能文献

小马体内劳拉西泮和对乙酰氨基酚结合物的肠肝循环

Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies.

作者信息

Greenblatt D J, Engelking L R

机构信息

Department of Psychiatry, Tufts University School of Medicine, Boston, Massachusetts.

出版信息

J Pharmacol Exp Ther. 1988 Feb;244(2):674-9.

PMID:3346841
Abstract

Adult female ponies (130-225 kg) with chronically implanted external biliary fistulas (T-tubes) participated in three-way cross-over studies using either i.v. lorazepam (10 mg) or acetaminophen (2 g), two model drugs biotransformed mainly by hepatic conjugative reactions. The objectives were to determine the systemic pharmacokinetics, urinary and biliary excretion and degree of enterohepatic circulation (EHC) of these compounds. Trial conditions were: A: EHC intact, with blood and urine, but not bile, collected after i.v. drug administration; B: EHC interrupted, with blood, urine and bile collected after i.v. drug administration; and C: bile infused, EHC open, without i.v. drug administration, with bile collected from trial B (containing biliary excreted drug) infused into the duodenum via the T-tube, followed by collection of blood, urine and bile. At least 2 weeks elapsed between trials. Interruption of the EHC caused lorazepam plasma half-life to shorten (3.4 vs. 2.3 hr with the EHC intact, P less than .1), clearance to increase (9.2 vs. 12.3 ml/min/kg, P less than .1) and total area under the plasma concentration curve for lorazepam glucuronide to decrease (210 vs. 310 ng/ml X hr, P less than .06). Recovery of lorazepam as its glucuronide in bile was 24.5% of the i.v. injected dose. Urinary elimination of lorazepam glucuronide was reduced from 41 to 36% of the dose due to bile collection. Subsequent duodenal infusion of collected bile, containing an average of 2.45 mg of lorazepam as glucuronide, was followed by urinary excretion of 0.48 mg of lorazepam as glucuronide in urine and 0.36 mg re-excreted into bile.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

体重130 - 225千克、长期植入外部胆管瘘(T型管)的成年雌性小马参与了三项交叉研究,使用静脉注射劳拉西泮(10毫克)或对乙酰氨基酚(2克),这两种模型药物主要通过肝脏结合反应进行生物转化。目的是确定这些化合物的全身药代动力学、尿液和胆汁排泄以及肝肠循环(EHC)程度。试验条件为:A:肝肠循环完整,静脉注射药物后采集血液和尿液,但不采集胆汁;B:肝肠循环中断,静脉注射药物后采集血液、尿液和胆汁;C:胆汁输注,肝肠循环开放,不进行静脉注射药物,将试验B中采集的胆汁(含经胆汁排泄的药物)通过T型管注入十二指肠,随后采集血液、尿液和胆汁。试验之间至少间隔2周。肝肠循环中断导致劳拉西泮血浆半衰期缩短(肝肠循环完整时为3.4小时,中断后为2.3小时,P小于0.1),清除率增加(9.2对12.3毫升/分钟/千克,P小于0.1),劳拉西泮葡萄糖醛酸苷的血浆浓度曲线下总面积减少(210对310纳克/毫升×小时,P小于0.06)。胆汁中劳拉西泮葡萄糖醛酸苷的回收率为静脉注射剂量的24.5%。由于采集胆汁,劳拉西泮葡萄糖醛酸苷的尿液消除量从剂量的41%降至36%。随后向十二指肠输注平均含2.45毫克劳拉西泮葡萄糖醛酸苷的采集胆汁,之后尿液中排泄了0.48毫克劳拉西泮葡萄糖醛酸苷,0.36毫克重新排泄到胆汁中。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验